Archive for March 2019

There’s more brewing in US health reform than ever. Is this good or bad for the world of pharma?   When Obamacare passed, big pharma privately smiled  –  anticipating bigger US markets (as “everyone” got insurance) and bigger profits (as drugmakers stayed a step ahead of pricing reforms). This glee turned out to be… all…

Several clients have asked what Commissioner Gottlieb’s departure will mean – to their own industries and other FDA constituencies. To ponder the question, I replaced my private consultant hat with my old “bureaucrat’s hat” from my days with CMS and FDA.   As I considered the question, and digested the trade press, I realized the…

The drug pipeline is filled with high-priced, high-impact cures. Drug price reforms might kill them – is there any cure for the cure? Anyone who’s read a US newspaper in the last year knows the politicians are trying to tackle the very real problem of very expensive drugs. Branded drugs are quite expensive for a…